Quick Answer
Nasus Pharma Ltd reported Diluted EPS of $0.72 per share (loss) for fiscal year 2025.
Nasus Pharma Ltd Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.72 | -227.3% |
| 2024 | -$0.22 | -10.0% |
| 2023 | -$0.20 | — |
- Nasus Pharma Ltd showed a decrease of -227.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Nasus Pharma Ltd’s diluted eps has declined by 260.0% (from $0.20 per share (loss) to $0.72 per share (loss)).
- The most recent figure is from Nasus Pharma Ltd’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: